Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaDel Pharma reports $1.31m net loss in Q3
NovaDel Pharma’s loss from operations was $1.52m, compared to $1.28m for the comparable period in 2009. For the nine months ended 30 September 2010, NovaDel has posted a
NovaDel Pharma’s loss from operations was $1.52m, compared to $1.28m for the comparable period in 2009. For the nine months ended 30 September 2010, NovaDel has posted a
Bohai Pharma has posted a net income of $3m for the first quarter 2010, or $0.15 per diluted share, compared to net income of $1.9m, or $0.15 per
Collis previously was executive vice president of AmerisourceBergen and president of AmerisourceBergen Drug (ABDC), the company’s largest subsidiary. Prior to that he was executive vice president of AmerisourceBergen
GSK and Fiocruz have established a relationship in 1985 to manufacture vaccines for public health priorities in Brazil. These include polio, Haemophilus influenzae type b (Hib), measles, mumps,
Meda CEO Anders Lonner said that OTC products is a growing segment and the acquisition of OTC brands further strengthens their presence in this area. The aquired products
Ablynx and Boehringer Ingelheim have signed an agreement in September 2007 to collaborate on the discovery, development and commercialisation of up to 10 different Nanobody therapeutics across areas
Echo Therapeutics is developing needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and Prelude SkinPrep System for transdermal drug delivery. Echo said that
ThermoDox is a proprietary heat-activated liposomal encapsulation of Doxorubicin. Celsion said that ThermoDox is currently being evaluated under a special protocol assessment with the US Food and Drug
As per the terms of the non-exclusive agreement, Boehringer Ingelheim will have access to VTU Technology’s ready-to-use high expression Pichia system in close collaboration with the VTU team
Compound libraries will be screened at the Michigan High Throughput Screening Center under the direction of Robert Kilkuskie. The company said that the antibodies developed in this program